Monte Rosa Therapeutics Analyst Ratings
Monte Rosa Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 64.67% | Credit Suisse | → $11 | Reiterates | Neutral → Neutral |
| 05/12/2023 | 64.67% | Credit Suisse | → $11 | Reiterates | Neutral → Neutral |
| 03/17/2023 | 64.67% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 01/03/2023 | 184.43% | Wells Fargo | → $19 | Upgrades | Equal-Weight → Overweight |
| 10/13/2022 | 229.34% | UBS | → $22 | Initiates Coverage On | → Buy |
| 08/15/2022 | 199.4% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 05/12/2022 | 214.37% | Piper Sandler | $40 → $21 | Maintains | Overweight |
| 04/28/2022 | 184.43% | Credit Suisse | → $19 | Initiates Coverage On | → Neutral |
| 02/10/2022 | 184.43% | Wells Fargo | → $19 | Initiates Coverage On | → Equal-Weight |
| 10/14/2021 | 199.4% | SVB Leerink | → $20 | Initiates Coverage On | → Market Perform |
| 07/19/2021 | 349.1% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 07/19/2021 | 498.8% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 07/19/2021 | 468.86% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | 64.67% | 瑞士信貸 | → 11 美元 | 重申 | 中性 → 中性 |
| 05/12/2023 | 64.67% | 瑞士信貸 | → 11 美元 | 重申 | 中性 → 中性 |
| 03/17/2023 | 64.67% | 瑞士信貸 | 12 美元 → 11 美元 | 維護 | 中立 |
| 01/03/2023 | 184.43% | 富國銀行 | → 19 美元 | 升級 | 重量相等 → 超重 |
| 2022 年 10 月 13 日 | 229.34% | 瑞銀（UBS） | → 22 美元 | 啓動覆蓋開啓 | → 購買 |
| 08/15/2022 | 199.4% | 傑富瑞 | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
| 2022 年 12 月 5 日 | 214.37% | 派珀·桑德勒 | 40 美元 → 21 美元 | 維護 | 超重 |
| 04/28/2022 | 184.43% | 瑞士信貸 | → 19 美元 | 啓動覆蓋開啓 | → 中立 |
| 2022 年 10 月 2 日 | 184.43% | 富國銀行 | → 19 美元 | 啓動覆蓋開啓 | → 重量相等 |
| 2021 年 10 月 14 日 | 199.4% | SVB Leerink | → 20 美元 | 啓動覆蓋開啓 | → 市場表現 |
| 07/19/2021 | 349.1% | 古根海姆 | → 30 美元 | 啓動覆蓋開啓 | → 購買 |
| 07/19/2021 | 498.8% | 派珀·桑德勒 | → 40 美元 | 啓動覆蓋開啓 | → 超重 |
| 07/19/2021 | 468.86% | 摩根大通 | → 38 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics（GLUE）的目標價格是多少？
The latest price target for Monte Rosa Therapeutics (NASDAQ: GLUE) was reported by Credit Suisse on August 11, 2023. The analyst firm set a price target for $11.00 expecting GLUE to rise to within 12 months (a possible 64.67% upside). 6 analyst firms have reported ratings in the last year.
瑞士信貸於2023年8月11日公佈了Monte Rosa Therapeutics（納斯達克股票代碼：GLUE）的最新目標股價。這家分析公司將目標股價定爲11.00美元，預計GLUE將在12個月內升至11.00美元（可能上漲64.67％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics（GLUE）的最新分析師評級是多少？
The latest analyst rating for Monte Rosa Therapeutics (NASDAQ: GLUE) was provided by Credit Suisse, and Monte Rosa Therapeutics reiterated their neutral rating.
Monte Rosa Therapeutics（納斯達克股票代碼：GLUE）的最新分析師評級由瑞士信貸提供，Monte Rosa Therapeutics重申了其中性評級。
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics（GLUE）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Monte Rosa Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Monte Rosa Therapeutics的最後一次評級是在2023年8月11日提交的，因此你應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
分析師對蒙特羅莎治療公司（GLUE）的評級正確嗎？
While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a reiterated with a price target of $0.00 to $11.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $6.68, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的蒙特羅莎治療公司（GLUE）評級得到了重申，目標股價爲0.00美元至11.00美元。Monte Rosa Therapeutics（GLUE）目前的交易價格爲6.68美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。